Recent studies found that expression of the coagulation-initiating CD142 is upregulated on circulating monocytes from patients with COVID-19, an increase that was linked with enhanced disease severity and mortality.33 Incubation of monocytes with all 4 SPM tested led to an overall downregulation of CD142, reaching statistical significance for RvD2 treatment of nonclassical monocytes (Figure 6B through 6D). Here, F3 is linked to COVID-19.